^
Association details:
| Biomarker: | POLE mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Published date:
10/16/2023
Excerpt:
To evaluate POLE LOP as a predictive biomarker a cohort of pts with POLE mutant mCRC treated with immunotherapy (IO) (n=29) was identified from institutional databases. All 7 pts with POLE LOP achieved clinical benefit (3 CR, 3 PR, 1 SD) and remain on immunotherapy at the time of submission (median follow up time = 36 months)....CRC tumors with LOP POLE mutation were found to have deep, sustained response to IO therapy, in contrast to those with non-LOP POLE mutations.
